Lidofast

Lidocaine, the active ingredient in Lidofast, is a local anesthetic presented as a sterile solution for urethral use. It provides temporary loss of sensation to the urethral mucosa, facilitating diagnostic and therapeutic procedures and relieving urethral discomfort. It is indicated for short‑term anesthesia during procedures such as cystoscopy, urethral dilation, and catheter insertion, providing rapid onset and reversible effect.

GNH USA supplies Lidofast as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality assurance and regulatory compliance.

Lidofast (lidocaine) is used as a local anesthetic applied to the urethral mucosa to achieve temporary sensory blockade.

- Cystoscopic procedures: provides analgesia and reduces discomfort during bladder and urethral examination. - Urethral catheterization: eases insertion and removal by numbing the urethral lining. - Urethral dilation: facilitates smooth passage of dilators by minimizing pain and spasm.

Lidofast may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Burning or stinging sensation at the application site - Mild local irritation or erythema - Transient dizziness or light‑headedness - Nausea - Headache - Mild metallic taste

Serious or Rare Side Effects: - Seizures or convulsions - Cardiac arrhythmias or conduction disturbances - Methemoglobinemia - Severe allergic reaction (anaphylaxis) - Respiratory depression - Persistent numbness beyond expected duration

When using Lidofast, several precautions should be observed to minimize risk and ensure safe administration.

- Allergy assessment: confirm no known hypersensitivity to lidocaine or amide‑type anesthetics - Dosage accuracy: use the prescribed volume and concentration only - Cardiac conditions: avoid in patients with severe heart block or conduction abnormalities - Liver impairment: adjust use in patients with significant hepatic dysfunction - Concurrent CNS depressants: monitor for enhanced central nervous system effects - Store at ambient temperature: keep in original container, protect from moisture and light

Lidofast can interact with other medicines, altering its safety profile or effectiveness.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): may cause severe cardiotoxicity - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase lidocaine plasma levels - Epinephrine in high concentrations: can potentiate systemic toxicity

Moderate Interactions (Monitor Closely): - Other local anesthetics: additive neuro‑ or cardiotoxic effects - Beta‑blockers: may enhance bradycardia - Diuretics (e.g., furosemide): may increase plasma lidocaine concentration